Claire M Rice

ORCID: 0000-0002-9851-4426
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Multiple Sclerosis Research Studies
  • Mesenchymal stem cell research
  • Neurogenesis and neuroplasticity mechanisms
  • Hepatitis C virus research
  • Pluripotent Stem Cells Research
  • Peripheral Neuropathies and Disorders
  • Long-Term Effects of COVID-19
  • Cardiovascular Syncope and Autonomic Disorders
  • Nerve injury and regeneration
  • COVID-19 Clinical Research Studies
  • Systemic Lupus Erythematosus Research
  • Retinal and Optic Conditions
  • RNA Interference and Gene Delivery
  • RNA regulation and disease
  • Microtubule and mitosis dynamics
  • Cerebral Palsy and Movement Disorders
  • Hematopoietic Stem Cell Transplantation
  • Infectious Encephalopathies and Encephalitis
  • IgG4-Related and Inflammatory Diseases
  • Cerebral Venous Sinus Thrombosis
  • Liver Disease Diagnosis and Treatment
  • Genomics, phytochemicals, and oxidative stress
  • Genetic Neurodegenerative Diseases
  • Infectious Diseases and Tuberculosis
  • Autoimmune and Inflammatory Disorders Research

Southmead Hospital
2015-2024

St. James's Hospital
2010-2024

University of Bristol
2015-2024

North Bristol NHS Trust
2016-2024

Trinity College Dublin
2020-2021

University College London
2020

Moorfields Eye Hospital
2020

University Hospitals Bristol NHS Foundation Trust
2020

Bristol Eye Hospital
2020

University Hospitals Bristol and Weston NHS Foundation Trust
2020

Summary. In postnatal life, mesenchymal stem cells (MSC) self‐replicate, proliferate and differentiate into tissues, including bone, fat, tendon, muscle bone marrow (BM) stroma. Possible clinical applications for MSC in cell transplantation have been proposed. We evaluated the frequency, phenotype differentiation potential of adult BM, cord blood (CB) peripheral collections (PBSC). During culture, BM proliferated to confluence 10–14 d, maintaining a stable non‐haemopoietic phenotype, HLA...

10.1046/j.1365-2141.2003.04284.x article EN British Journal of Haematology 2003-04-01

<h3>Importance</h3> Within 2 decades of onset, 80% untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied never using validated definition. <h3>Objective</h3> To determine the use, type of, timing DMTs risk MS diagnosed <h3>Design, Setting, Participants</h3> Cohort study prospective data from...

10.1001/jama.2018.20588 article EN JAMA 2019-01-15

Cellular immune responses, particularly those mediated by CD8+ CTL, may be important in the pathogenesis and control of hepatitis C virus (HCV) infection. To define role HCV-specific CTL chronic C, activity liver peripheral blood was assessed 35 patients with HCV infection 5 non-HCV controls. expanded cells evaluated against autologous lymphoblastoid transduced recombinant vaccinia vectors expressing genotype 1a Ags. detected unprimed bulk-expanded derived from 16 patients, but not...

10.4049/jimmunol.158.3.1473 article EN The Journal of Immunology 1997-02-01

Abstract SARS-CoV-2 is associated with new-onset neurological and psychiatric conditions. Detailed clinical data, including factors recovery, are lacking, hampering prediction modelling targeted therapeutic interventions. In a UK-wide cross-sectional surveillance study of adult hospitalized patients during the first COVID-19 wave, multi-professional input from general sub-specialty neurologists, psychiatrists, stroke physicians, intensivists, we captured detailed data on demographics, risk...

10.1093/braincomms/fcab168 article EN cc-by Brain Communications 2021-01-01

The European Stroke Organisation (ESO) guideline on Primary Angiitis of the Central Nervous System (PACNS), developed according to ESO standard operating procedures (SOP) and Grading Recommendations, Assessment, Development Evaluation (GRADE) methodology, was elaborated assist clinicians in diagnostic treatment pathway patients with PACNS their decision making. A working group involving vascular neurologists, neuroradiologists, rheumatologists, a neuropathologist methodologist identified 17...

10.1177/23969873231190431 article EN European Stroke Journal 2023-10-30

Fifty-nine elderly residents of long-term care facilities who had DSM-III diagnoses dementia were studied in an 8-week randomized, double-blind comparison trial haloperidol, oxazepam, and diphenhydramine to test the efficacy these agents treatment clinically significant behavioral disturbances patients with dementia. All three demonstrated modest but as measured by clinician ratings agitated behavior activities daily living. The absolute magnitude improvement was greater for haloperidol than...

10.1176/ajp.147.12.1640 article EN American Journal of Psychiatry 1990-12-01

In this phase I study, we assessed the safety and feasibility of intravenous, autologous bone marrow (BM) cell therapy, without immunosuppressive preconditioning, in six patients with clinically definite, relapsing-progressive multiple sclerosis (MS). Assessment efficacy was a secondary objective employed clinical disability rating scales, multimodal evoked potential (MMEP) recordings, magnetic resonance imaging (MRI) scans. Cells were harvested, filtered infused intravenously day-case...

10.1038/clpt.2010.44 article EN Clinical Pharmacology & Therapeutics 2010-05-05

Recent studies have investigated the potential of autologous bone marrow-derived mesenchymal stem cells (MSCs) as a therapy for multiple sclerosis. Whether MSCs from individuals with sclerosis are functionally and/or phenotypically abnormal has received less attention. Through our Phase I clinical trial, SIAMMS, we were able to isolate and characterize The objective study was demonstrate that show no significant differences derived without isolated marrow aspirates four SIAMMS participants....

10.1177/1352458510371959 article EN Multiple Sclerosis Journal 2010-06-11

Aim: The aims of this study were to investigate the prevalence atrial fibrillation (AF), treatment rates AF and factors underlying awareness treatment, in a large nationally representative study. Methods: A population sample people aged 50+, living Republic Ireland, recruited as part Irish longitudinal on ageing. Ten-minute electrocardiogram recordings obtained (n = 4890), analysed detect AF. Self-reported arrhythmias, subjective objective health measures (cardiovascular diseases,...

10.1093/qjmed/hct060 article EN QJM 2013-03-14

Cerebellar ataxia commonly occurs in multiple sclerosis, particularly chronic progressive disease. Previous reports have highlighted both white matter and grey pathological changes within the cerebellum; demyelination inflammatory cell infiltrates appear commonly. As Purkinje axons are sole output of cerebellar cortex, understanding pathologic processes these cells is crucial to develop strategies prevent their loss thus reduce ataxia. We studied occurring cerebellum. Using immunohistochemic...

10.1111/bpa.12230 article EN Brain Pathology 2014-11-20

With the notable exceptions of dementia, stroke, and motor neuron disease, relatively little is known about safety utility percutaneous endoscopic gastrostomy (PEG) tube insertion in patients with neurodegenerative disease. We aimed to determine PEG feeding context disease complete a literature review order identify whether particular factors need be considered improve outcome.A retrospective case note referred for by neurologists single neuroscience center was conducted according...

10.5946/ce.2016.106 article EN cc-by-nc Clinical Endoscopy 2016-10-13

Autologous bone-marrow-derived cells are currently employed in clinical studies of cell-based therapy multiple sclerosis (MS) although the bone marrow microenvironment and marrow-derived isolated from patients with MS have not been extensively characterised.To examine assess proliferative potential multipotent mesenchymal stromal (MSCs) progressive MS.Comparative phenotypic analysis MSCs control subjects was undertaken.In marrow, there an interstitial infiltrate inflammatory lymphoid...

10.1177/1352458517711276 article EN cc-by Multiple Sclerosis Journal 2017-05-26

Defects in motor protein-mediated neuronal transport mechanisms have been implicated a number of neurodegenerative disorders but remain relatively little studied Alzheimer's disease (AD). Our aim the present study was to assess expression anterograde kinesin superfamily pr oteins KIF5A, KIF1B, and KIF21B, examine their relationship levels hyperphosphorylated tau, amyloid-β protein precursor (AβPP), (Aβ) human brain tissue. We used combination qPCR, immunoblotting, ELISA perform these...

10.3233/jad-170094 article EN Journal of Alzheimer s Disease 2017-10-17

Treatment persistence is the continuation of therapy over time. It reflects a combination treatment efficacy and tolerability. We aimed to describe real-world rates on disease-modifying therapies (DMTs) for people with multiple sclerosis (pwMS) reasons DMT discontinuation.

10.1111/ene.16289 article EN cc-by European Journal of Neurology 2024-04-03

Systemic delivery of multipotent mesenchymal stem cells (MSC) may be benefit in the treatment neurological diseases, including multiple sclerosis (MS). Certainly, animal studies have demonstrated functional benefits following MSC transplantation, although mechanisms by which MSCs migrate to lesions and stimulate repair remain unknown. Chemokines migration other settings. In this study, we systematically explore migratory proliferative responses human (hMSC) chemokines expressed MS lesions....

10.4161/cam.4.2.11404 article EN Cell Adhesion & Migration 2010-04-01

Background: Peroxisomes are organelles in eukaryotic cells with multiple functions including the detoxification of reactive oxygen species, plasmalogen synthesis and β-oxidation fatty acids. Recent evidence has implicated peroxisomal dysfunction models sclerosis (MS) disease progression. Objectives: Our aims were to determine whether there changes peroxisomes MS grey matter (GM) compared control GM. Methods: We analysed cases GM immunocytochemically assess membrane protein (PMP70) neuronal...

10.1177/1352458513505691 article EN Multiple Sclerosis Journal 2013-09-25
Coming Soon ...